AVXL Anavex Life Sciences Corp.

0.5915USD-11.39%Mkt Cap: 54.83M USDP/E: —

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and r…

Institutional holders20 on file

Key Statistics

Company
Market Cap54.83M USD
Enterprise Value-56.45M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-46.38M USD
Revenue/Share—
Last Price0.5915 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees34
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.08
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.49
EPS (TTM)-0.14 USD
EPS (Forward)-0.55 USD
52W Range
0.59010% of range7.600
52W High7.600 USD
52W Low0.5901 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-48.89%
ROA-44.67%
ROIC—
ROCE-54.15%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.04M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-49.35%
Net Debt-118.33M USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio15.62
Quick Ratio15.51
Book Value/Sh1.21 USD
Cash/Share1.28 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateOct 7, 2015
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.92.70M
Float89.81M
Insiders1.71%
Institutions43.27%
Short Interest
Short Ratio8.2d
Short % Float13.09%
Short % Out.12.86%
Shares Short11.92M
Short (prev mo.)13.57M
Technical
SMA 501.629 (-63.7%)
SMA 2002.838 (-79.2%)
Beta1.25
S&P 52W Chg12.00%
Avg Vol (30d)1.23M
Avg Vol (10d)1.38M
Technical Indicators
RSI (14)16.9
MACD-0.2492
MACD Signal-0.2279
MACD Hist.-0.0213
BB Upper1.519 USD
BB Middle1.055 USD
BB Lower0.5917 USD
BB Width87.87%
ATR (14)0.1061 USD
Vol Ratio (20d)1.41x

About Anavex Life Sciences (NASDAQ: AVXL)

›

Anavex Life Sciences (NASDAQ: AVXL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 34 employees.

The shares were at 0.5915 USD on 20 November 2026, down 91.9% over 52 weeks. Its 52-week range is 0.5901 USD to 7.600 USD, and it trades at the bottom of that range.

Its market capitalisation is 54.83M USD.

Anavex Life Sciences reports return on equity of -48.9% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 118.33M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 24 November 2026.